NASDAQ:MNPR

Monopar Therapeutics - MNPR Stock Forecast, Price & News

$1.79

-0.01 (-0.56%)

(As of 08/17/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.71
▼
$1.80
50-Day Range: $1.79
▼
$2.39
52-Week Range: $1.70
▼
$6.98

Volume: 4,826 shs
Average Volume: 9,595 shs
Market Capitalization: $22.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Monopar Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 235.3% Upside
$6.00 Price Target
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

858th out of 1,122 stocks

Pharmaceutical Preparations Industry

431st out of 551 stocks

3.5

Analyst's Opinion

Consensus Rating
Monopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Monopar Therapeutics has a forecasted upside of 235.3% from its current price of $1.79.
Amount of Analyst Coverage
Monopar Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of Monopar Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monopar Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Monopar Therapeutics has recently increased by 38.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Monopar Therapeutics does not currently pay a dividend.
Dividend Growth
Monopar Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNPR.

2.0

News and Social Media Coverage

News Sentiment
Monopar Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Monopar Therapeutics this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.20% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.62% of the stock of Monopar Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Monopar Therapeutics are expected to remain at ($0.80) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monopar Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monopar Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monopar Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Stock Performance

MNPR traded down $0.06 during trading on Wednesday, reaching $1.74. 12 shares of the company were exchanged, compared to its average volume of 8,572. The company's 50-day moving average is $2.16 and its two-hundred day moving average is $2.44. Monopar Therapeutics has a 12-month low of $1.70 and a 12-month high of $6.98.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price target on Monopar Therapeutics from $9.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday.

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Stock News Headlines

August 11, 2022 | msn.com

Monopar Therapeutics: Q2 Earnings Insights

August 11, 2022 | finance.yahoo.com

Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments

July 24, 2022 | americanbankingnews.com

Monopar Therapeutics (NASDAQ:MNPR) Shares Up 0.5%

May 12, 2022 | finance.yahoo.com

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

May 12, 2022 | finance.yahoo.com

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

March 24, 2022 | benzinga.com

Recap: Monopar Therapeutics Q4 Earnings

March 24, 2022 | seekingalpha.com

Monopar Therapeutics GAAP EPS of -$0.21 misses by $0.02

March 24, 2022 | finance.yahoo.com

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

March 8, 2022 | finance.yahoo.com

Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

March 8, 2022 | finance.yahoo.com

Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

February 15, 2022 | finance.yahoo.com

Monopar Announces Clinical and Preclinical Program Updates

February 15, 2022 | finance.yahoo.com

Monopar Announces Clinical and Preclinical Program Updates

January 17, 2022 | nasdaq.com

Monopar Therapeutics Inc. Common Stock (MNPR)

January 7, 2022 | finance.yahoo.com

Monopar to Present at the H.C. Wainwright BioConnect Conference

December 23, 2021 | nasdaq.com

Monopar Therapeutics Inc Shares Approach 52-Week Low - Market Mover

December 23, 2021 | nasdaq.com

Monopar Therapeutics Inc Shares Close the Day 12.7% Lower - Daily Wrap

December 8, 2021 | finance.yahoo.com

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

November 12, 2021 | finance.yahoo.com

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

October 27, 2021 | finance.yahoo.com

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

September 16, 2021 | finance.yahoo.com

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

September 14, 2021 | finanznachrichten.de

Monopar Therapeutics Inc.: Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

September 13, 2021 | finance.yahoo.com

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

September 9, 2021 | finance.yahoo.com

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

August 12, 2021 | finance.yahoo.com

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

August 5, 2021 | benzinga.com

Soft Tissue Cancer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Company Calendar

Last Earnings: 11/12/2021
Today: 8/18/2022
Next Earnings (Estimated): 11/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNPR
CUSIP: N/A
CIK: 1645469
Web: www.monopartx.com
Phone: 847-388-0349
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +235.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -58.04%
Return on Assets: -53.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.61
Quick Ratio: 7.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 12,726,000
Free Float: 7,483,000
Market Cap: $22.78 million
Optionable: Not Optionable
Beta: 0.47

Key Executives

Dr. Chandler D. Robinson M.B.A. (Age 38)
M.D., M.Sc., MBA, MSc, Co-Founder, CEO, Pres & Director
Comp: $659.6k
Ms. Kim R. Tsuchimoto CPA (Age 59)
CFO, Sec. & Treasurer
Comp: $327.8k
Mr. Andrew J. Cittadine M.B.A. (Age 50)
Chief Operating Officer
Dr. Patrice P. Rioux M.D. (Age 71)
Ph.D., Acting Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

UBS Group AG
Bought 16,455 shares on 8/11/2022
Ownership: 0.155%

View All Insider Transactions
View All Institutional Transactions

MNPR Stock - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNPR shares.
View MNPR analyst ratings or view top-rated stocks.
What is Monopar Therapeutics' stock price forecast for 2022?: 2 analysts have issued 1 year target prices for Monopar Therapeutics' shares. Their MNPR share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 235.3% from the stock's current price.
View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts.
How have MNPR shares performed in 2022?: Monopar Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, MNPR stock has decreased by 44.2% and is now trading at $1.7897.
View the best growth stocks for 2022 here.
When is Monopar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our MNPR earnings forecast.
How were Monopar Therapeutics' earnings last quarter?: Monopar Therapeutics Inc. (NASDAQ:MNPR) released its earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02.
What other stocks do shareholders of Monopar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

When did Monopar Therapeutics IPO?: (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.
What is Monopar Therapeutics' stock symbol?: Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."
Who are Monopar Therapeutics' major shareholders?: Monopar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.16%).
View institutional ownership trends.
How do I buy shares of Monopar Therapeutics?: Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Monopar Therapeutics' stock price today?: One share of MNPR stock can currently be purchased for approximately $1.79.
How much money does Monopar Therapeutics make?: Monopar Therapeutics (NASDAQ:MNPR) has a market capitalization of $22.78 million. The company earns $-9,100,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.
How can I contact Monopar Therapeutics?: Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The official website for the company is www.monopartx.com. The company can be reached via phone at 847-388-0349 or via email at info@monopartx.com.

This page (NASDAQ:MNPR) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Monopar Therapeutics - MNPR Stock Forecast, Price & News

Monopar Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month